<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="212">
  <stage>Registered</stage>
  <submitdate>18/10/1999</submitdate>
  <approvaldate>18/10/1999</approvaldate>
  <nctid>NCT00004342</nctid>
  <trial_identification>
    <studytitle>International Registry for Severe Chronic Neutropenia</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>UW-730</secondaryid>
    <secondaryid>199/11901</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neutropenia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Severe chronic neutropenia (SCN), i.e.: Absolute neutrophil
        count less than 500/mm3 on 3 occasions within the last 3 months (less than 200/mm3 for
        cyclic neutropenia) Bone marrow aspirate consistent with SCN History of infection No drug
        induced neutropenia No myelodysplastic syndrome No aplastic anemia No thrombocytopenia or
        anemia unless due to Shwachman-Diamond syndrome or glycogen storage disease type IB Prior
        enrollment on Amgen SCN trials eligible Bone marrow aspiration within 1 year required
        Cytogenetic evaluation strongly suggested --Prior/Concurrent Therapy-- At least 5 years
        since prior chemotherapy --Patient Characteristics-- No rheumatoid arthritis No systemic
        lupus erythematosus No HIV seropositivity</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/1994</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Central Highlands Oncology Program - Ballarat</hospital>
    <postcode>3350 - Ballarat</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Center for Research Resources (NCRR)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Washington</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>OBJECTIVES: I. Document the clinical course of severe chronic neutropenia (SCN).

      II. Monitor and assess long term safety of primary treatment in SCN patients in the United
      States, Canada, Europe, and Australia.

      III. Study the incidence and outcome of adverse events such as osteoporosis, splenomegaly,
      cytogenetic abnormalities, myelodysplastic syndrome, and leukemia.

      IV. Evaluate growth and development and hematologic parameters. V. Monitor for clinically
      significant changes in primary treatment response over time.

      VI. Establish a physician network to increase the understanding of SCN. VII. Establish a
      demographic database to allow for future research.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00004342</trialwebsite>
    <publication>Dale DC, Bonilla MA, Boxer L, et al.: Development of AML/MDS in a subset of patients (PTS) with severe chronic neutropenia (SCN). Blood 84(10 suppl 1): 518a, 1994.
Guerra J, Withers DA, Boxer LM. Myb binding sites mediate negative regulation of c-myb expression in T-cell lines. Blood. 1995 Sep 1;86(5):1873-80.
Welte K, Dale D. Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol. 1996 Apr;72(4):158-65. Review.
Kalra R, Dale D, Freedman M, Bonilla MA, Weinblatt M, Ganser A, Bowman P, Abish S, Priest J, Oseas RS, Olson K, Paderanga D, Shannon K. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood. 1995 Dec 15;86(12):4579-86.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Chandler Dale</name>
      <address>University of Washington</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>